We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.31%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$118M
AUM Growth
+$4.41M
Cap. Flow
-$8.19M
Cap. Flow %
-6.92%
Top 10 Hldgs %
44.84%
Holding
84
New
17
Increased
12
Reduced
22
Closed
11

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$6.63M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.31M
3
CLLS
Cellectis
CLLS
+$1.61M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$1.21M
5
BLRX
BioLineRX
BLRX
+$1.07M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$2.56M
2
AERI
Aerie Pharmaceuticals
AERI
+$2.3M
3
DERM
Dermira, Inc.
DERM
+$2.28M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.21M
5
TSRO
TESARO, Inc.
TSRO
+$2.08M

Sector Composition

Rank Sector Weight
1 Healthcare 85.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
26
Rigel Pharmaceuticals
RIGL
$712M
$1.57M 1.33%
+47,348
New +$1.21M
ADXS
27
DELISTED
Advaxis Inc
ADXS
$1.41M 1.19%
11,467
-200
-2% -$26K
XENE icon
28
Xenon Pharmaceuticals
XENE
$6.28B
$1.36M 1.15%
339,614
-174,477
-34% -$1.37M
QURE icon
29
uniQure
QURE
$2.52B
$1.18M 1%
203,907
– –
JNJ icon
30
Johnson & Johnson
JNJ
$643B
$1.17M 0.99%
9,400
– –
SCYX icon
31
SCYNEXIS
SCYX
$36M
$1.05M 0.89%
4,774
+2,603
+120% +$655K
NDRM
32
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$994K 0.84%
37,438
-483
-1% -$12K
BLRX
33
BioLineRX
BLRX
$12.2M
$961K 0.81%
+1,667
New +$1.07M
DERM
34
DELISTED
Dermira, Inc.
DERM
$955K 0.81%
28,000
-70,800
-72% -$2.28M
VYGR icon
35
Voyager Therapeutics
VYGR
$184M
$944K 0.8%
+71,320
New +$865K
ELOS
36
DELISTED
Syneron Medical Ltd
ELOS
$907K 0.77%
85,947
– –
TNDM icon
37
Tandem Diabetes Care
TNDM
$1.22B
$869K 0.74%
72,429
– –
ARQL
38
DELISTED
Arqule Inc
ARQL
$855K 0.72%
807,008
+138,273
+21% +$184K
ACHN
39
DELISTED
Achillion Pharmaceuticals
ACHN
$827K 0.7%
196,500
– –
NERV icon
40
Minerva Neurosciences
NERV
$199M
$821K 0.69%
+12,665
New +$984K
BLUE
41
DELISTED
bluebird bio
BLUE
$818K 0.69%
695
– –
EXAC
42
DELISTED
Exactech Inc
EXAC
$797K 0.67%
31,636
– –
STXS icon
43
Stereotaxis
STXS
$128M
$782K 0.66%
1,372,862
– –
CASC
44
DELISTED
Cascadian Therapeutics, Inc.
CASC
$767K 0.65%
+185,259
New +$779K
NVDQ
45
DELISTED
Novadaq Technologies Inc.
NVDQ
$747K 0.63%
95,841
-6,000
-6% -$42.5K
NEOS
46
DELISTED
Neos Therapeutics, Inc
NEOS
$686K 0.58%
95,273
+56,400
+145% +$350K
ZGNX
47
DELISTED
Zogenix, Inc.
ZGNX
$649K 0.55%
59,778
-14,760
-20% -$150K
AKBA icon
48
Akebia Therapeutics
AKBA
$341M
$648K 0.55%
+70,455
New +$688K
CGNT
49
DELISTED
Cogentix Medical, Inc.
CGNT
$636K 0.54%
353,482
– –
MTVA
50
MetaVia Inc
MTVA
$7.39M
$554K 0.47%
+1
New +$661K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, DAFNA Capital Management held 84 positions worth $118M, up 3.9% from $114M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

DAFNA Capital Management withdrew a net $8.19M in Q1 2017, closing 11 positions and reducing 22 holdings. Its most notable exit was Cytokinetics, an estimated $2.56M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 82% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Cellectis worth $1.83M.

  • DAFNA Capital Management's largest Q1 2017 buy was Cellectis: 76,404 shares worth $1.83M.
  • DAFNA Capital Management added most to Loxo Oncology, Inc in Q1 2017, an estimated $6.63M increase.
  • DAFNA Capital Management's biggest Q1 2017 reduction was Aerie Pharmaceuticals, cutting an estimated $2.3M.
  • DAFNA Capital Management fully exited Cytokinetics in Q1 2017, selling an estimated $2.56M.
  • DAFNA Capital Management's ten largest holdings make up 45% of its $118M portfolio in Q1 2017.
  • DAFNA Capital Management opened 17 new positions and closed 11 in Q1 2017.
  • DAFNA Capital Management's portfolio value rose 3.9% quarter-over-quarter to $118M.

Based on DAFNA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.